FDA grants priority review of sutimlimab, potential first approved treatment of hemolysis for cold agglutinin disease.- Sanofi
The FDA has granted priority review of Sanofi’s Biologics License Application (BLA) for sutimlimab for the treatment of hemolysis in adult patients with cold agglutinin disease (CAD). Sutimlimab,… read more.